Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Irritable bowel syndrome: therapeutic evaluation of indigenous drugs
PMC 5667251
Baez-Duarte BG, Mendoza-Carrera F, Garcia-Zapien A, Flores-Martinez SE, Sanchez-Corona J, Zamora-Ginez I, Torres-Rasgado E, Leon-Chavez BA, Perez-Fuentes R, Multidisciplinary Research Group on Diabetes of the Instituto Mexicano del Seguro S
Representative domains include: Gastrointestinal and hepatic models: Protection against ulcers, leaky gut, IBSlike symptoms, Crohntype inflammation, and toxic liver injury (e.g., CCl4, NSAID, and alcohol models), with improved mucosal healing and barrier integrity
Active compound: BPC-157 + GHK-Cu + TB-500 + KPV
Most of these residues are conserved or replaced by similar amino acid residues in PfGrx or other enzymatically active glutaredoxins
US$ 28.12
US$ 20.82
US$ 20.72
